Chiron S P A
USPTO Trademark & Patent Filings
Trademark applications and grants for Chiron S P A. Chiron S P A has 1 trademark applications. The latest application filed is for "ACELLUVAX"
- Company Aliases
- Chiron S.p.A.
- Chiron S.P.A. -
- Chiron S.P.A. - Siena IT
- Chiron Spa - Siena IT I-53100
Trademarks Patents
| Patent Application | Date |
|---|---|
| Neisserial antigens 20080131421 - 10/864684 Scarlato; Vincenzo ; et al. | 2008-06-05 |
| Combination neisserial compositions 20070231342 - 10/982703 Giuliani; Marzia Monica ; et al. | 2007-10-04 |
| Polyepitope carrier protein 20070003566 - 11/030635 Rappuoli; Rino ; et al. | 2007-01-04 |
| Non-toxic mucosal adjuvant 20060177469 - 11/399571 Rappuoli; Rino | 2006-08-10 |
| Polypeptide-vaccines for broad protetion against hypervirulent meningococcal lineages 20060171957 - 10/530753 Pizza; Mariagrazia | 2006-08-03 |
Mark Image Registration | Serial | Trademark Application Date |
|---|---|
"ACELLUVAX" 75850975 |
ACELLUVAX 1999-11-18 |
| NCAGE Code | A0468 | CHIRON SPA |
| CAGE Code | A0468 | CHIRON SPA |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 